|
|
| | Voriconazole-d3 Basic information |
| Product Name: | Voriconazole-d3 | | Synonyms: | (2R,3S/2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (RaceMic Voriconazole);(2S,3R)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol;(2S,3R)-rel-2-(2,4-Difluorophenyl)-3-(5-fluoropyriMidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol;Voriconazole
PI-6;(2R,3R)-Voriconazole;(R *, S *) 3- (5-fluoropyrimidin-4-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl ) -2-butanol;(2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol;3R)-2-(2 | | CAS: | 188416-29-7 | | MF: | C16H14F3N5O | | MW: | 349.31 | | EINECS: | 1312995-182-4 | | Product Categories: | | | Mol File: | 188416-29-7.mol |  |
| | Voriconazole-d3 Chemical Properties |
| Boiling point | 508.6±60.0 °C(Predicted) | | density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Storage temp. 2-8°C | | pka | 11.54±0.29(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/s3 | | InChIKey | BCEHBSKCWLPMDN-NLBNCHMPNA-N | | SMILES | C[C@@H]([C@@](CN1C=NC=N1)(C1C(F)=CC(F)=CC=1)O)C1C(F)=CN=CN=1 |&1:1,2,r| |
| | Voriconazole-d3 Usage And Synthesis |
| Description | Voriconazole-d3 is an Ergosterol biosynthesis inhibitor and a labeled form of Voriconazole. This mono triazole antifungal agent inhibits the growth of Candida, Cryptococcus, and Aspergillus species. Studies suggest that Voriconazole-d3 can be synthesized by modifying the structure of fluconazole. This antifungal agent functions by inhibiting cytochrome P450 dependent 14-α-sterol demethylase, which is responsible for the biosynthesis of Ergosterol. Furthermore, Voriconazole-d3 inhibits fungal growth, cell wall thinning, and cell membrane degradation. | | Uses | Voriconazole is a triazole antifungal agent used primarily in the treatment or prevention of aspergillosis and candidal infections. However, its therapy may cause transient, asymptomatic serum aminotransferase elevations, and it is also a well-known cause of acute drug-induced liver injury. | | Application | Voriconazole-d3 is derived from 2,4-Difluoro-α-(1H-1,2,4-triazolyl)acetophenone, which is an antifungal activity, particularly toward Candida albicans and Candida parapsilosis. | | References | 1. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species DOI:10.1128/AAC.41.8.1840
Belanger, P., et al. 1997. Antimicrob. Agents Chemother. 41: 1840-1842. PMID: 9257776
2. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
Marco, F., et al. 1998. Antimicrob. Agents Chemother. 42: 161-163. PMID: 9449278
3. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
Espinel-Ingroff, A. 1998. J. Clin. Microbiol. 36: 198-202. PMID: 9431946 |
| | Voriconazole-d3 Preparation Products And Raw materials |
|